EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR ‐T Cell Therapy in B‐Cell Malignancies

Jiaqi Guo, Linyu Li, Xiaoxi Zhou, Dan Li, Shaolong He, Lifang Huang, Yicheng Zhang, Yafang Guo, Weiwei Tian, Jie Zhao, Jia Wei

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 17.11.2026. Verfasst von Jiaqi Guo und 10 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Given that CD19 chimeric antigen receptor T (CAR‐T) cell therapy frequently induces severe thrombocytopenia and recombinant human thrombopoietin (rhTPO)′s role in managing this CAR‐T‐associated cytopenia remains not well defined, we aimed to evaluate rhTPO's safety and efficacy for treating thrombocytopenia in B‐cell malignancy patients after tandem dual‐target (CD19/20 or CD19/22) CAR‐T therapy.

Methods

A multicenter retrospective study (2018–2024) enrolled 53 patients. rhTPO was administered for platelets < 50 × 10 9 /L or bleeding risk; platelet counts were monitored for 4 weeks post‐treatment initiation. Results rhTPO was initiated pre/post‐CAR‐T (median 7 days post‐infusion, 13‐day duration). Baseline platelets (25 × 10 9 /L) rose to 25, 26, 48 × 10 9 /L at 7, 14, 28 days post‐rhTPO. Of 38 transfusion‐requiring patients, 71.1% achieved ≥ 20 × 10 9 /L without transfusion by day 28. rhTPO did not affect CAR‐T expansion. Cytokine release syndrome (CRS) occurred in 77.4% (17.0% grade ≥ 3), immune effector cell‐associated neurotoxicity syndrome (ICANS) in 13.2% (all grade 1), and the 30‐day infection rate was 41.5%; no rhTPO‐related toxicities were observed. Conclusion rhTPO effectively manages peri‐CAR‐T thrombocytopenia in B‐cell malignancy patients, with no elevated risks of CRS, ICANS, or infections.

Zitieren

APA

Guo, J., Li, L., Zhou, X., Li, D., He, S., Huang, L., Zhang, Y., Guo, Y., Tian, W., Zhao, J., & Wei, J. (2026). A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR ‐T Cell Therapy in B‐Cell Malignancies. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72421

Vancouver

Guo J, Li L, Zhou X, Li D, He S, Huang L, et al. A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR ‐T Cell Therapy in B‐Cell Malignancies. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72421

BibTeX
@article{Guo2026,
  author = {Guo, Jiaqi and Li, Linyu and Zhou, Xiaoxi and Li, Dan and He, Shaolong and Huang, Lifang and Zhang, Yicheng and Guo, Yafang and Tian, Weiwei and Zhao, Jie and Wei, Jia},
  title = {A Real‐World Study on the Use of Recombinant Human Thrombopoietin for Managing Thrombocytopenia Following Tandem Dual‐Target CAR ‐T Cell Therapy in B‐Cell Malignancies},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72421}
}
Kostenlos starten →